The present study evaluated the advantages of Ga-68-PSMA-11 in 108 patients with BCR of prostate cancer after primary treatment with curative intent at 60 and 120–180 min after the injection of radiopharmaceutical. This evidence concerns the gene BCR and prostate carcinoma.